Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunvozertinib plus Anlotinib in EGFR-mutated NSCLC with co-mutations
NCT06355609Phase 2Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of sunvozertinib in non-small cell lung cancer (NSCLC), sponsored by Hunan Cancer Hospital. Started Jul 2024; status: recruiting.
02
Drugs
sunvozertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06355609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06355609.